![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/20/2901487/0/en/Vaxxinity-UB-312-Parkinson-s-Trial-Results-Published-in-Nature-Medicine.html
https://www.fiercebiotech.com/biotech/vaxxinity-retreats-abusive-relationship-after-3-years-public-markets
https://www.globenewswire.com/news-release/2024/04/19/2866409/0/en/Vaxxinity-Issues-Shareholder-Letter.html
https://www.globenewswire.com/news-release/2024/04/19/2866373/0/en/Vaxxinity-Announces-Intention-to-Voluntarily-Delist-and-Deregister-its-Class-A-Common-Stock.html
https://www.globenewswire.com/news-release/2024/03/28/2854092/0/en/Vaxxinity-to-Present-Clinical-Data-at-the-Annual-Academy-of-Neurology-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/03/27/2853637/0/en/Vaxxinity-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Updates.html
https://www.globenewswire.com//news-release/2024/03/07/2842413/0/en/Vaxxinity-Announces-Positive-Target-Engagement-Data-from-Phase-1-Clinical-Trial-for-Parkinson-s-Disease-at-AD-PD-2024.html
https://www.globenewswire.com//news-release/2024/02/15/2829936/0/en/Vaxxinity-s-Cholesterol-Vaccine-Candidate-Successfully-Lowers-LDL-C-Preclinical-Data-Published.html
https://www.globenewswire.com//news-release/2024/02/13/2828226/0/en/Vaxxinity-to-Present-Clinical-and-Preclinical-Pipeline-Data-at-AD-PD-2024.html
https://www.globenewswire.com/news-release/2024/01/30/2819963/0/en/Vaxxinity-Announces-Research-Collaboration-on-Active-Immunotherapies-for-Neurodegenerative-Diseases-with-University-of-Florida.html